Dr Odilie Bagwell, AU D CCC-A | |
4200 State Road 524, Suite 103, Cocoa, FL 32926-3560 | |
(321) 504-4327 | |
(321) 504-4387 |
Full Name | Dr Odilie Bagwell |
---|---|
Gender | Female |
Speciality | Audiologist |
Location | 4200 State Road 524, Cocoa, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083925648 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | AY 989 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Odilie Bagwell, AU D CCC-A 4200 State Road 524, Suite 103, Cocoa, FL 32926-3560 Ph: (321) 504-4327 | Dr Odilie Bagwell, AU D CCC-A 4200 State Road 524, Suite 103, Cocoa, FL 32926-3560 Ph: (321) 504-4327 |
News Archive
A synthetic cannabis-like drug in a pill was safe and effective in treating obstructive sleep apnea in the first large multi-site study of a drug for apnea funded by the National Institutes of Health. The study was conducted at Northwestern Medicine and the University of Illinois at Chicago.
VeriChip Corporation ("VeriChip") and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing partnership with RECEPTORS to continue the development of a triage detection system for detection of the H1N1 virus.
A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.
Melanoma is the least common but one of the most deadly skin cancers. It accounts for only about one percent of all cases globally, but the majority of skin cancer deaths.
Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, today announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB.
› Verified 2 days ago